Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J's HIV drug rilpivirine passes Phase III trials but stumbles on virologic failure

This article was originally published in Scrip

Executive Summary

Johnson & Johnson's non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (TMC278) was safe and effective in two Phase III trials of treatment-naïve HIV-patients, showed data presented last week at the 18th International AIDS conference in Austria. Both the ECHO and THRIVE studies met their primary endpoint – non-inferiority of rilpivirine to Merck & Co's NNRTI Sustiva (efavirenz), as assessed by the proportion of patients achieving an undetectable viral load (less than 50 copies per ml) at week 48.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts